BIOHIT PLC.    STOCK EXCHANGE RELEASE   3.10.2000  AT  14:30     1 (3)

Biohit's test panel for screening the risk of gastric cancer and peptic
ulcer from blood samples has successfully passed the extensive clinical
evaluations  performed  at the Jorvi Hospital in  Finland.  During  the
evaluation  100  patients  underwent gastroscopy  and  the  microscopic
examination  of  the  biopsies taken from the mucous  membrane  of  the
stomach.  Various types of gastric diseases were diagnosed  in  approx.
40%   of  the  patients  participating  in  the  study.  Moreover,  the
Pepsinogen I and Gastrin 17 -concentrations and the Helicobacter pylori
(H.  pylori)  antibodies were determined from blood  samples  by  using
Biohit's  test panel. When the results produced by Biohit's test  panel
were  compared with the diagnoses made on the basis of the  gastroscopy
and  biopsies, it was found that the sensitivity of the test panel  was
over 90%, i.e., the test panel finds nearly all those patients who have
been  diagnosed ill on the basis of the results of the gastroscopy  and
analysis of the biopsy samples. Furthermore, the test panel was able to
classify correctly, with a specificity of 90%, those patients  who  did
not suffer from a gastric disease or the disease was mild.

In  nearly 90% of the cases the infection of the mucous membrane of the
stomach  (gastritis), atrophic gastritis and peptic ulcer is caused  by
the  H.  pylori infection. It has also been observed that the H. pylori
infection is connected with the development of gastric cancer.  Approx.
80%  of  the cases of gastric cancer develops on the basis  of  the  H.
pylori infection. The risk of gastric cancer increases exponentially in
connection  with  atrophic gastritis, and this risk is approx.  90-fold
for  those  persons who suffer from severe atrophic  gastritis  of  the
entire stomach compared with persons who have a healthy mucous membrane
of  the stomach. In addition to gastric cancer, the H. pylori infection
and  the gastritis caused by it, as well as atrophic gastritis make the
patient  prone also for peptic ulcer. The risk of peptic ulcer  depends
on the severity of the changes caused by the infections and atrophy and
their  location  in the stomach. Thus, the severity of  the  underlying
different stomach disorders, which are difficult to diagnose, may  vary
from  gastritis  to gastric cancer. So far, the only useful  method  of
diagnosing  these  various  conditions has  been  gastroscopy  and  the
microscopic  examination of the biopsies. Gastroscopy is  uncomfortable
for  the  patient, time-consuming and expensive. Moreover, it is  never
performed during the first visit of the patient to the doctor  and,  in
addition,  the  resources  of  specialized  doctors  are  limited   for
performing gastroscopies.

In  accordance with the consensus recommendation made by experts  in  a
meeting  in Maastricht two weeks ago, a patient suffering from  stomach
disorders   and  the  H.  pylori  infection  should  be  treated   with
antibiotics  and antacids. The same applies to patients suffering  from
atrophic gastritis. Biohit's unique test panel enables any doctor to
                                                                 2 (3)

diagnose  such diseases fast, reliably and easily without  gastroscopy.
The  examination made with the test panel prior to treatment ensures  a
rapid  and  accurate diagnosis, and, as a result, renders the treatment
more  effective, is more comfortable for the patient and produces  cost
savings in health care.

If  the  results produced by Biohit's test panel require a  gastroscopy
and  biopsies  to be taken, the doctor already knows  what  kind  of  a
disease  (infection, atrophy or neoplasia) he is  looking  for  and  in
which  part  of  the stomach (upper part, i.e., corpus or  lower  part,
i.e.,  antrum) it is located. Likewise, it is possible to  detect  from
the  results produced by the test panel whether the possible  ulcer  is
located in the antrum or the duodenum. The test panel facilitates  also
finding such patients whose secretion of acids has increased. Thus, the
results  of  the tests performed from the blood sample of the  patient,
which correlate with the condition of the entire stomach, increase  the
reliability  of the gastroscopic and biopsy sample examinations,  which
are dependent on the experience and skills of the doctor.

Biohit's  test panel enables the identification of atrophic  gastritis,
which  is  located in the corpus area of the stomach and leads  usually
without  any  noticeable symptoms to anemia, neurological  damages  and
increases  the  risk  of  dementia. This is caused  by  the  fact  that
atrophic   gastritis  hinders  the  absorption  of  vitamin  B-12   and
eventually leads to a deficiency of the said vitamin. The deficiency of
vitamin B-12 causes gradually disturbances in cell metabolism, and as a
result,  the level of homocysteine of serum increases. A high level  of
homocysteine   in   blood  is,  on  its  part,  a   risk   factor   for
arteriosclerosis  and thrombosis. Biohit's method for  determining  the
concentration  of  vitamin B-12 in blood, currently under  development,
has  received  a positive search report concerning the European  patent
application  covering 16 countries. A Finnish patent has  been  awarded
for  Biohit's test panel for screening the risk of gastric  cancer  and
peptic  ulcer. The objective of Biohit's aggressive patent strategy  is
to  submit  patent  applications in all those  market  areas  in  which
potential copying of Biohit's products might take place, and in which a
significant amount of the Company's products are sold or are  estimated
to  be  sold, namely certain European countries, Japan, Russia and  the
U.S.  According to the information received from the National Board  of
Patents and Registration in Finland on January 27, 2000 Biohit  had  at
that  stage 16 patents in Finland and the rest of the twenty  companies
recently listed in Finland altogether 11 Finnish patents.

The  global  market potential for Biohit's diagnostic  tests  has  been
estimated  to  be USD 5,0 billion. Biohit is currently  commencing  the
marketing  of  its diagnostic tests through its seven subsidiaries  and
numerous  distributors, as well as negotiations concerning co-operation
with  large  multinational diagnostic companies, e.g. in Japan,  France
and  Canada.  In  certain Asian and Near Eastern  countries  Biohit  is
negotiating with the representatives of Ministries of Health on the
                                                                 3 (3)

deliveries  of Biohit's diagnostics test systems to develop the  health
care  sectors  of the said countries. In addition to diagnostic  tests,
Biohit  is  currently able to offer complete diagnostic  test  systems,
which  are  comprised of Biohit's liquid handling products,  diagnostic
tests,  analyzers  and related software used for  the  calculation  and
interpretation  of the results. These test systems are complemented  by
Biohit's maintenance and training services.

In  1999  the  net  sales of the Biohit Group totalled  to  MFIM  122,2
million. In January-June 2000 the net sales totalled to MFIM 65,4 (MFIM
61,7  in  1999).  The  net  sales were generated  primarily  by  liquid
handling  products  and  their disposable tips.  As  a  result  of  the
directed  share  issue  carried out in June 1999,  the  Company  raised
approx. MEUR 9,0 in new capital (2,0 million B-shares, EUR 4,5 / share)
and  listed on the New Market (NM) -list of the Helsinki Exchanges. The
closing  price  of  Biohit's share on Oct. 2, 2000 was  EUR  7,05.  The
overall  development  of the price of the B-share  has  been  favorable
during the past 12 months demonstrating a growth of 63,57%.

Additional information:  Osmo Suovaniemi, President & CEO, tel: +358-9-
                         773 861, direct: +358-9-773 86 250, mobile:
                         +358-50 556 5605, fax: +358-9-773 86 205


Distribution:            Helsinki Exchanges
                         The Financial Supervisory Authority